Stryker Corporation: Stryker Receives FDA Clearance for Waste Management System
Stryker Corporation (NYSE: SYK) announced today that its Instruments division has received 510(k) clearance for the Neptune 2 Waste Management System from the U.S. Food and Drug Administration (FDA). The Neptune 2 Waste Management System minimizes risk to healthcare workers by eliminating harmful exposure to fluids and smoke in the operating room. This constantly closed system collects and disposes of surgical waste without operator assistance to prevent contact with infectious fluids and surgical plumes.
With the 510(k) clearance of the Neptune 2, Stryker's commitment has never been stronger to the surgical waste management market, patient and caregiver safety and supporting hospital goals related to sustainability, efficiency and cost optimization. Insight from healthcare workers and perspectives from regulatory agencies helped create the upgraded Neptune 2 surgical waste management system. The result is added safety features, greater ease of use, expanded labeling and training modules, all aimed at helping surgical staff make the OR environment as modern, safe and efficient as possible.
Beyond the Neptune 2 product upgrades, Stryker is also elevating patient and caregiver safety with our new, multi-module Continuing Education (CE) Surgical Suction Academy.
Stryker is one of the world's leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care. The Company offers a diverse array of innovative medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products to help people lead more active and satisfying lives. For more information about Stryker, please visit www.stryker.com.
For media inquiries please contact: Yin Becker, Stryker Corporation, 201-831-5000 or email@example.com
For investor inquiries please contact: Katherine A. Owen, Stryker Corporation, 269-385-2600 or firstname.lastname@example.org
This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to the Rejuvenate and ABG II matter; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system; changes in financial markets; changes in the competitive environment; our ability to integrate acquisitions, including the acquisition of MAKO Surgical Corp.; and our ability to realize anticipated cost savings as a result of workforce reductions and other restructuring activities. Additional information concerning these and other factors are contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.